

**VX-509 (Decernotinib) is a potent and selective Janus kinase 3 (JAK3) inhibitor that attenuates inflammation in animal models of autoimmune disease**

Sudipta Mahajan, James K. Hogan, Dina Shlyakhter, Luke Oh, Francesco G. Salituro, Luc Farmer and Thomas C. Hoock

**Supplemental Table 1. ATP and peptide substrate concentrations used in kinase assays of VX-509.**

Kinase	[ATP], $\mu\text{M}$	[peptide]	Peptide	Assay Format
AURA (AUR2)	50	800 $\mu\text{M}$	LRRASLG	Spectrophotometric
CDK2/cyclin A	200	300 $\mu\text{M}$	MAHHRSPRKRAKKK	Spectrophotometric
CIT	10	0.2 mg/mL	KKRNRSLV	Radiometric
COT	10	1 $\mu\text{M}$	inactive MEK1	Radiometric
cMET	200	10 $\mu\text{M}$	polyE4Y	Radiometric
ERK2	65	800 $\mu\text{M}$	ATGPLSPGPFGR	Spectrophotometric
FAK	70	0.5 mg/mL	polyE4Y	Radiometric
FLT3	90	0.5 mg/mL	polyE4Y	Radiometric
GCK	500	1.2 mg/mL	MBP	Spectrophotometric
GSK3 $\beta$	20	300 $\mu\text{M}$	HSSPHQ(Sp)EDEEE	Spectrophotometric
IRAK4	800	300 $\mu\text{M}$	HMRSAMSGHLVKRR	Spectrophotometric
ITK	15	2 $\mu\text{M}$	SAM68	Radiometric
JAK1	27	0.25 mg/mL	polyE4Y	Radiometric
JAK2	12	0.5 mg/mL	polyE4Y	Radiometric
JAK3	5	0.25 mg/mL	polyE4Y	Radiometric
JNK3	20	200 $\mu\text{M}$	KRELVELTTPSGEAPNQALLR	Spectrophotometric
KDR	300	10 $\mu\text{M}$	polyE4Y	Spectrophotometric
KIT	700	0.5 mg/mL	polyE4Y	Radiometric
P38 $\alpha$	200	400 $\mu\text{M}$	KRELVELTTPSGEAPNQALLR	Spectrophotometric
PI3K $\gamma$	15	30 $\mu\text{M}$	Phosphatidylinositol bisphosphate	Radiometric
PKA	5	50 $\mu\text{M}$	LRRASLG	Spectrophotometric
PknA	15	6 $\mu\text{M}$	GarA	Radiometric
PknB	3	4 $\mu\text{M}$	GarA	Radiometric
PknG	6	6 $\mu\text{M}$	GarA	Radiometric
PLK1	20	4 $\mu\text{M}$	SAM68	Radiometric
ROCK1	15	45 $\mu\text{M}$	KKRNRSLV	Radiometric
Src	50	0.3 mg/mL	polyE4Y	Spectrophotometric
SYK	50	0.1 mg/mL	polyE4Y	Radiometric
TAK1	50	18 $\mu\text{M}$	MBP	Radiometric
TYK2	14	0.25 mg/mL	polyE4Y	Radiometric

Supplemental Table 2. ATP, peptide, and protein concentrations used in assays of VX-509.

Kinase Assay	ATP ( $\mu$ M)	ATP $K_M$ ( $\mu$ M)	[peptide substrate]	Peptide Substrate
ABL	45	48	50 $\mu$ M	EAIYAAPFAKKK
ALK	200	229	250 $\mu$ M	KKKSPGEYVNIEFG
AMPK	90	80	200 $\mu$ M	AMARAASAAALARRR
ASK1	200	371	0.33 mg/mL	MBP
AXL	90	80	250 $\mu$ M	KKSRGDYMTMQIG
BLK	120	125	0.1 mg/mL	polyE4Y
CAMKII	15	22	30 $\mu$ M	KKLNRTLVA
CDK1/CycB	45	51	0.1 mg/mL	Histone H1
CDK5/P35	15	30	0.1 mg/mL	Histone H1
CHK1	90	84	200 $\mu$ M	KKKVSRSGLYRSPSPENLNRPR
CK1	45	38	200 $\mu$ M	KRRRALS(p)VASLPGL
EGFR	10	3	0.1 mg/mL	polyE4Y
EphB4	10	11	0.1 mg/mL	polyE4Y
ERK1 (MAPK1)	70	67	250 $\mu$ M	RRELVEPLTPSGEAPNQALLR
FES	45	50	0.1 mg/mL	polyE4Y
FGFR3	15	28	0.1 mg/mL	polyE4Y
Flt1 (VEGFR1)	200	2118	250 $\mu$ M	KKKSPGEYVNIEFG
FYN	70	64	250 $\mu$ M	KVEKIGEGTYGVVYK
IKK $\alpha$	10	6	200 $\mu$ M	KKKKERLLDDRHDSDLDSMKDEE
IKK $\beta$	10	7	100 $\mu$ M	KKKKERLLDDRHDSDLDSMKDEE
IR	200	447	250 $\mu$ M	KKSRGDYMTMQIG
JNK1 (SAPK1 $\gamma$ )	45	41	3 $\mu$ M	ATF2
LCK	90	95	250 $\mu$ M	KVEKIGEGTYGVVYK
LYN	70	79	0.1 mg/mL	polyE4Y
MEK1	10	ND	1 $\mu$ M	inactive MAPK2
MKK6	10	ND	1 $\mu$ M	inactive SAPK2a
MKK7	10	ND	2 $\mu$ M	inactive JNK1a1
MSK1	90	76	30 $\mu$ M	GRPRTSSFAEGKK
MST2	155	165	0.33 mg/mL	MBP
NEK2	120	120	0.33 mg/mL	MBP
P38 $\beta$ (SAPK2 $\beta$ )	45	58	0.33 mg/mL	MBP
PAK2	90	89	30 $\mu$ M	KEAKEKRQEIAKRRRLSSLRASTSKSGGSQ K
PDGFR $\alpha$	120	106	0.1 mg/mL	polyE4Y
PKC $\beta$ II	70	58	0.1 mg/mL	Histone H1
PKC $\zeta$	155	170	50 $\mu$ M	ERMRPKRQGSVRRRV
PKC $\theta$	15	16	0.1 mg/mL	Histone H1
PLK3 (FNK)	70	70	2 mg/mL	casein
PRAK	15	18	30 $\mu$ M	KKLRRTLVA
PRK2	15	10	30 $\mu$ M	AKRRRLSSLRA
RAFc	45	49	0.66 mg/mL	MBP
RET	70	58	250 $\mu$ M	KKKSPGEYVNIEFG
RIPK2 (RICK)	120	133	0.33 mg/mL	MBP
ROCK II	15	22	30 $\mu$ M	KEAKEKRQEIAKRRRLSSLRASTSKSGGSQ K
RON	70	74	250 $\mu$ M	KKSRGDYMTMQIG
ROS (KROS)	200	563	250 $\mu$ M	KKKSPGEYVNIEFG
RSK3	10	7	30 $\mu$ M	KKKNRTLVA
SGK	90	93	30 $\mu$ M	GRPRTSSFAEGKK
TIE2	200	439	0.1 mg/mL	polyE4Y
TrkA	120	129	250 $\mu$ M	KKKSPGEYVNIEFG
ZIPK	15	14	250 $\mu$ M	KKLNRTLSFAEPG

**Supplemental Table 3.** K<sub>i</sub>, IC<sub>50</sub>, or percent inhibition values for VX-509 in kinase assays.

Enzyme	Result Value <sup>a</sup>	Result Type	Enzyme	Result Value <sup>a</sup>	Result Type
AURA (AUR2)	> 0.8	Ki (μM)	KDR (VEGFR)	> 4	Ki (μM)
CDK2/CycA	2.6 ± 0.8	Ki (μM)	KIT	> 2.5	Ki (μM)
CIT	> 10	IC <sub>50</sub> (μM)	cMET	> 4	Ki (μM)
COT	> 4	Ki (μM)	P38α(SAPK2α)	> 4	Ki (μM)
ERK2 (MAPK2)	> 4	Ki (μM)	PI3Kγ	> 4	Ki (μM)
FAK	>10	IC <sub>50</sub> (μM)	PKA	> 4	Ki (μM)
FLT3	1.0 ± 0.3	Ki (μM)	PknA	> 10	IC <sub>50</sub> (μM)
GCK	71 ± 16	% inhibition @ 3 uM	PknB	8	IC <sub>50</sub> (μM)
GSK3β	1.8 ± 0.6	Ki (μM)	PknG	> 10	IC <sub>50</sub> (μM)
IRAK4	> 4	Ki (μM)	PLK1	> 4	Ki (μM)
ITK	> 4	Ki (μM)	ROCK I	1.5 ± 0.4	Ki (μM)
JAK1	0.011 ± 0.002	Ki (μM)	SRC	> 4	Ki (μM)
JAK2	0.013 ± 0.004	Ki (μM)	SYK	> 4	Ki (μM)
JAK3	0.0025 ± 0.0007	Ki (μM)	TAK1	> 4	Ki (μM)
JNK3 (SAPK1β)	> 4	Ki (μM)	TYK2	0.011	Ki (μM)

**Supplemental Table 4.** Selectivity profile of VX-509 for kinases from the KinaseProfiler™ assay.

Enzyme	% inh @ 2 $\mu$ M	Enzyme	% inh @ 2 $\mu$ M	Enzyme	% inh @ 2 $\mu$ M
ABL	28	FYN	4	PKC $\iota$	0
ALK	0	IKK $\alpha$	0	PKC $\theta$	21
AMPK	46	IKK $\beta$	1	PLK3 (FNK)	0
ASK1	0	IR	3	PRAK	0
AXL	0	JNK1 (SAPK1c)	0	PRK2	71
BLK	14	LCK	4	RAFc	12
CAMKII	31	LYN	28	RET	0
CDK1/CycB	22	MEK1	0	RIPK2 (RICK)	0
CDK5/P35	55	MKK6	0	ROCK II	55
CHK1	0	MKK7	0	RON	0
CK1	0	MSK1	8	ROS (KROS)	0
EGFR	0	MST2	64	RSK3	27
EphB4	20	NEK2	0	SGK	0
ERK1 (MAPK1)	0	P38 $\beta$ (SAPK2 $\beta$ )	3	TIE2	37
FES	42	PAK2	0	TrkA	48
FGFR3	26	PDGFR $\alpha$	0	ZIPK	0
Flt1 (VEGFR1)	19	PKC $\beta$ II	30		